DRDO-Developed Drug '2-Deoxy-D-Glucose' Gets DCGI Approval for Emergency Use in Moderate to Severe COVID-19 Patients
The DCGI has granted permission for emergency use of therapeutic application of drug 2-deoxy-D-glucose (2-DG) as adjunct therapy in moderate to severe COVID-19 patients.
DRDO-Developed Drug '2-Deoxy-D-Glucose' Gets DCGI Approval for Emergency Use in Moderate to Severe COVID-19 Patients
The drug has been developed by DRDO lab Institute of Nuclear Medicine & Allied Sciences in collaboration with Dr Reddy’s Laboratories. Clinical trial have shown that this molecule helps in faster recovery of hospitalized patients & reduces supplemental oxygen dependence: DRDO
— ANI (@ANI) May 8, 2021
The drug comes in powder form in sachet, which is taken orally by dissolving it in water. It accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production: DRDO
— ANI (@ANI) May 8, 2021
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)
(The above story first appeared on LatestLY on May 08, 2021 01:40 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).
